medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2015, Number 1

<< Back Next >>

Rev Invest Clin 2015; 67 (1)

Sarcoidosis: A Single Hospital-Based Study in a 24-Year Period

Carrillo-Pérez DL, Apodaca-Cháveza EI, Carrillo-Maravilla E, Mejía-Ávila M, Hernández-Oropeza JL, Reyes E, Atisha-Fregoso Y, Hernández-Molina G

Language: English
References: 31
Page: 33-38
PDF size: 188.94 Kb.


ABSTRACT

Background: Clinical presentation of sarcoidosis varies according to race and geographical area. We describe the clinical spectrum and outcome of sarcoidosis in Mexican patients compared with other populations. Methods: We reviewed the medical charts of 21 patients with sarcoidosis seen at a referral hospital in 1989-2012; organ involvement was assessed using the ACCESS instrument. We compared our results with the ACCESS and Latin American studies. We used descriptive statistics and reported odd ratios with 95% CI. Results and Conclusion: Fifty-two percent were women; median age was 31 years; median time to diagnosis, 5.5 months. Frequency of organ involvement was: constitutional symptoms 62%, lungs 66.6%, skin 42.8%, bone marrow 23.4%, lymph node 19%, liver 19%, and eye 19%. After one year of follow-up, 47.5% of patients were asymptomatic without treatment, 38% asymptomatic on treatment, and 14.2% symptomatic on treatment. In our patients, pulmonary involvement was lower (66.6 vs. 94.9%; p = 0.001) and cutaneous (42.8 vs.15.8%; p = 0.003) and bone marrow (23.4 vs. 4.7%; p = 0.001) were higher than in the ACCESS cohort. Data regarding Latin American populations was scarce. The clinical spectrum of sarcoidosis in our population differed from other studies, with a higher frequency of cutaneous sarcoidosis and less pulmonary involvement.


REFERENCES

  1. Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med. 2007;357:2153-65.

  2. Westney GE, Judson MA. Racial and ethnic disparities in sarcoidosis: from genetics to socioeconomics. Clin Chest Med. 2006;27:453-62.

  3. Sharma OP. Sarcoidosis around the world. Clin Chest Med. 2008; 29:357-63.

  4. Rybicki BA, Iannuzzi MC. Epidemiology of sarcoidosis: recent advances and future prospects. Semin Respir Crit Care Med. 2007;28:22-35.

  5. Edmondstone WM, Wilson AG. Sarcoidosis in Caucasians, Blacks and Asians in London. Br J Dis Chest. 1985;79:27-36.

  6. Morimoto T, Azuma A, Abe S, et al. Epidemiology of sarcoidosis in Japan. Eur Respir J. 2008;31:372-9

  7. Hunninghake GW, Costabel U, Ando M, et al. ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. Sarcoidosis Vasc Diffuse Lung Dis. 1999;16:149-73.

  8. Purriel P, Navarrete E. Epidemiology of sarcoidosis in Uruguay and other countries of Latin America. Am Rev Respir Dis. 1961; 84:155-61.

  9. Manieri-Hidalgo J, Monge-Bonilla C, Sanchez-Ramirez A. Sarcoidosis. Experiencia con 15 casos en el Hospital Calderón Guardia. Acta Med-Costarric. 2002;44:1-8

  10. Pila-Pérez R, Bestard-González A, Amador-Betancourt, et al. Sarcoidosis: estudio de 30 casos. Rev Cub Med. 1986;25:1027-37.

  11. Lemos-Silva V, Araújo PB, Lopes C, et al. Epidemiological characteristics of sarcoidosis patients in the city of Rio de Janeiro, Brazil. J Bras Pneumol. 2011;37:438-45.

  12. González EL, Vigliano C, Caneva J. Sarcoidosis. Presentación clínica y pronóstico. Medicina. 2010;70:499-502.

  13. Valdez-Ochoa S, Mejía-Cruz M. Sarcoidosis: Estudio de 26 casos con lesiones toracopulmonares. Rev Med Inst Mex Seguro Soc. 1982;20:613-19.

  14. Scadding JG. Prognosis of intrathoracic sarcoidosis in England. A review of 136 cases after five years’ observation. Br Med J. 1961;2:1165-72.

  15. Judson MA, Baughman RP, Teirstein AS, et al. Defining organ involvement in sarcoidosis: the ACCESS proposed instrument. ACCESS Research Group. A Case-Control Etiologic Study of Sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 1999;16:75-86.

  16. Baughman RP, Teirstein AS, Judson MA, et al. Case-control etiologic study of sarcoidosis (ACCESS) research group. Clinical characteristics of patients in a case-control study of sarcoidosis. Am J Respir Crit Care Med. 2001;164:1885-9.

  17. James DG, Neville E, Siltzbach LE. A worldwide review of sarcoidosis. Ann NY Acad Sci. 1976;278:321-34.

  18. Byg KE, Milman N, Hansen S. Sarcoidosis in Denmark 1980-1994. A registry-based incidence study comprising 5536 patients. Sarcoidosis Vasc Diffuse Lung Dis. 2003;20:46-52.

  19. Henke CE, Henke G, Elveback LR, et al. The epidemiology of sarcoidosis in Rochester, Minnesota: a population based study of incidence and survival. Am J Epidemiol. 1986;123:840-5

  20. Newman LS, Rose CS, Bresnitz EA, et al. ACCESS Research Group. A case control etiologic study of sarcoidosis: environmental and occupational risk factors. Am J Respir Crit Care Med. 2004;170:1324-30.

  21. Gupta D, Singh AD, Agarwal R, et al. Is tobacco smoking protective for sarcoidosis? A case-control study from North India. Sarcoidosis Vasc Diffuse Lung Dis. 2010;27:19-26.

  22. Gillman A, Steinfort C. Sarcoidosis in Australia. Intern Med J. 2007;37:356-9.

  23. Judson MA, Boan AD, Lackland DT. The clinical course of sarcoidosis: presentation, diagnosis, and treatment in a large white and black cohort in the United States. Sarcoidosis Vasc Diffuse Lung Dis. 2012;29:119-27.

  24. Baughman RP. Pulmonary sarcoidosis. Clin Chest Med. 2004; 25:521-30.

  25. Pietinalho A, Ohmichi M, Löfroos AB, et al. The prognosis of pulmonary sarcoidosis in Finland and Hokkaido, Japan. A comparative five-year study of biopsy-proven cases. Sarcoidosis Vasc Diffuse Lung Dis. 2000;17:158-66.

  26. Kıter G, Müsellim B, Cetinkaya E, et al. Clinical presentations and diagnostic work-up in sarcoidosis: a series of Turkish cases (clinics and diagnosis of sarcoidosis). Tuberk Toraks. 2011;59:248-58.

  27. Mana J, Morera J, Fite E, et al. Sarcoidosis in Spain. Sarcoidosis. 1994;9:259-62

  28. Rodrigues MM, Coletta EN, Ferreira RG, et al. Delayed diagnosis of sarcoidosis is common in Brazil. J Bras Pneumol. 2013;39:539-46.

  29. Smith-Rohrberg D, Sharma SK. Tuberculin skin test among pulmonary sarcoidosis patients with and without tuberculosis: its utility for the screening of the two conditions in tuberculosis-endemic regions. Sarcoidosis Vasc Diffuse Lung Dis. 2006;23:130-4.

  30. Gupta D, Chetty M, Kumar N, et al. Anergy to tuberculin in sarcoidosis is not influenced by high prevalence of tuberculin sensitivity in the population. Sarcoidosis Vasc Diffuse Lung Dis. 2003;20:40-5.

  31. Judson MA, Baughman RP, Thompson BW, et al. Two year prognosis of sarcoidosis: the ACCESS experience. Sarcoidosis Vasc Diffuse Lung Dis. 2003;20:204-11.




2020     |     www.medigraphic.com